Ctrl Worx Watch List › Company

Hepion Pharmaceuticals, Inc. (HEPA): material weakness open 1,398 days

By , Ctrl Worx™. Built from its own SEC filings. How the Clock works.

Hepion Pharmaceuticals, Inc. stated in 14 SEC filings since Apr 10, 2023 that it has one or more material weaknesses in its internal control over financial reporting. The filings gave no conclusion on whether that control is effective. The latest was its 10-Q for the period ended Jun 30, 2026.

Ctrl Worx Watch List™ status

On the Clock
3.8 yearsopen since Dec 31, 2022
10-Q, Aug 13, 2026latest filing that reports the weakness. Read it on SEC EDGAR
#513 of 1,250on the Clock by time open, tied with 45 other companies that share its start date. See the Clock

Still filing, and no annual report of its own says the weakness is fixed.

Checked against SEC EDGAR: Oct 29, 2026 · Entry #11037 · Agent-checked Oct 25, 2026

Filings with a weakness18
First in our dataMar 31, 2021
AuditorGrassi & Co., CPAs, P.C

Causes the company named

Complex or non-routine accounting · 17Tax · 17Segregation of duties · 11Entity-level and governance · 9Financial close and reporting · 9Accounting expertise and resources · 5ITGC: general · 1

Insufficient personnel, weak control environment, and inadequate controls over complex transactions and tax provisions.

What the latest filing says

re controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) of the Securities Exchange Act of 1934, as amended) required by paragraph (b) of Rule 13a-15 or Rule 15d-15, as of June 30, 2026, our Interim Principal Executive Officer/Principal Financial Officer has concluded that due to the material weaknesses in our internal control over financial reporting noted below, our disclosure controls and procedures were not effective. ● Due to cost-cutting measures, the Company’s control environment was ineffective as they did not maintain a sufficient complement of personnel to execute controls as designed including the absence of proper segregation of duties. Such impacted controls include indirect controls affecting risk assessment, information & communication, and monitoring components of COSO along with certain control activities including both business process controls and information technology general controls. ● Lack of proper design and implementation of controls over formal review, approval, and evaluation of non-core, complex accounting transactions. ● Lack [...]

From the controls section of the 10-Q filed Aug 13, 2026. Read the full filing on SEC EDGAR.

Company response: Hepion Pharmaceuticals, Inc. can send a statement or a link to its remediation update to russell@ctrlworx.com. We post it here, unedited and dated.

Filings

FiledFormPeriodControlsCausesFiling
Aug 13, 202610-QJun 30, 2026Material weakness stated, no ICFR conclusionSegregation of duties; Complex or non-routine accounting; Entity-level and governance; TaxEDGAR
May 14, 202610-QMar 31, 2026Material weakness stated, no ICFR conclusionSegregation of duties; Complex or non-routine accounting; Entity-level and governance; TaxEDGAR
Mar 12, 202610-KDec 31, 2025Material weakness stated, no ICFR conclusionSegregation of duties; Financial close and reporting; Complex or non-routine accounting; ITGC: general; Entity-level and governance; TaxEDGAR
Nov 12, 202510-QSep 30, 2025Material weakness stated, no ICFR conclusionSegregation of duties; Complex or non-routine accounting; TaxEDGAR
Aug 14, 202510-QJun 30, 2025Material weakness stated, no ICFR conclusionSegregation of duties; Complex or non-routine accounting; TaxEDGAR
May 19, 202510-QMar 31, 2025Material weakness stated, no ICFR conclusionSegregation of duties; Accounting expertise and resources; Complex or non-routine accounting; TaxEDGAR
Apr 8, 202510-KDec 31, 2024Material weakness stated, no ICFR conclusionSegregation of duties; Complex or non-routine accounting; Entity-level and governance; TaxEDGAR
Nov 14, 202410-QSep 30, 2024Material weakness stated, no ICFR conclusionSegregation of duties; Complex or non-routine accounting; TaxEDGAR
Aug 13, 202410-QJun 30, 2024Material weakness stated, no ICFR conclusionSegregation of duties; Complex or non-routine accounting; TaxEDGAR
May 21, 202410-QMar 31, 2024Material weakness stated, no ICFR conclusionSegregation of duties; Complex or non-routine accounting; TaxEDGAR
Apr 16, 202410-KDec 31, 2023Material weakness stated, no ICFR conclusionSegregation of duties; Financial close and reporting; Complex or non-routine accounting; Entity-level and governance; TaxEDGAR
Nov 20, 202310-QSep 30, 2023Material weakness stated, no ICFR conclusionFinancial close and reporting; Complex or non-routine accounting; TaxEDGAR
Aug 14, 202310-QJun 30, 2023Material weakness stated, no ICFR conclusionFinancial close and reporting; Complex or non-routine accounting; TaxEDGAR
Apr 10, 202310-KDec 31, 2022Material weakness stated, no ICFR conclusionFinancial close and reporting; Complex or non-routine accounting; TaxEDGAR
Apr 8, 202210-KDec 31, 2021EffectiveEDGAR
Nov 15, 202110-QSep 30, 2021Material weakness stated, no ICFR conclusionFinancial close and reporting; Accounting expertise and resources; Complex or non-routine accounting; Entity-level and governance; TaxEDGAR
Aug 16, 202110-QJun 30, 2021Material weakness stated, no ICFR conclusionFinancial close and reporting; Accounting expertise and resources; Complex or non-routine accounting; Entity-level and governance; TaxEDGAR
May 14, 202110-QMar 31, 2021Material weakness stated, no ICFR conclusionFinancial close and reporting; Accounting expertise and resources; Complex or non-routine accounting; Entity-level and governance; TaxEDGAR
Mar 31, 202110-KDec 31, 2020Material weakness stated, no ICFR conclusionFinancial close and reporting; Accounting expertise and resources; Entity-level and governanceEDGAR

Others on the Clock in the same industry

By SEC industry code: 2834, Pharmaceutical Preparations, then related codes.

Follow HEPA for free

Get an email when Hepion Pharmaceuticals, Inc files a 10-K or 10-Q that reports a material weakness, or says its controls are effective again.

Want the next one the day it's filed?

MW Pro sends an alert the day a company you follow reports a material weakness or says it fixed one. Founding price $990 a year.

Join the MW Pro waitlistLook up any company in Controls Radar™

Watch List Weekly: new material weaknesses, fixes and the longest-running cases, every Monday.

One email to confirm, then one email each Monday. Every email has a one-click unsubscribe. Privacy policy

Based on public SEC filings. Causes are grouped into standard categories by Ctrl Worx. The filings are the authority. Ctrl Worx is not affiliated with Hepion Pharmaceuticals, Inc. or the SEC. Not investment advice. Why you can rely on the Watch List.